Assessment of the Bioactivity of Antibodies against β -Amyloid Peptide *in vitro* and *in vivo*

M. Hasan Mohajeri Meret N.M. Gaugler Julia Martinez Jay Tracy Hong Li
Arames Cramer Katrin Kuehnle M. Axel Wollmer Roger M. Nitsch

Division of Psychiatry Research, University of Zürich, Zürich, Switzerland

Key Words

Alzheimer's disease · Immunization · Microglia

Abstract

The accumulation of the β -amyloid peptide ($A\beta$) is a central event in the pathogenesis of Alzheimer's disease (AD). $A\beta$ removal from the brain by immune therapy shows promising potential for the treatment of patients with AD, although the mechanisms of the antibody action are incompletely understood. In this study we compared the biological activities of antibodies raised against various $A\beta$ fragments for $A\beta$ reduction *in vitro* and *in vivo*. Antibodies against $A\beta$ enhanced the uptake of $A\beta_{42}$ aggregates up to 6-fold by primary microglial cells *in vitro*. The kinetics of $A\beta_{42}$ uptake varied considerably among antibodies. Based on the activity to mediate $A\beta_{42}$ uptake by microglial cells, we identified a bioactive antibody that significantly reduced $A\beta_{42}$ levels in the brains of transgenic mice with neuronal expression of an AD-related mutated amyloid precursor protein. This effect depended on the epitopes recognized by the antibody. Our data suggest that the ability to facilitate $A\beta_{42}$ uptake by primary microglia cells *in vitro* can be used to predict the biological activity of the antibody by passive

immunization *in vivo*. This protocol may prove useful for the rapid validation of the activity of antibodies designed to be used in immune therapy of AD.

Copyright © 2004 S. Karger AG, Basel

Introduction

Alzheimer's disease (AD), the most common cause of dementia, is an age-related neurodegenerative disorder that is characterized by progressive cognitive deficits, such as memory loss and a decline in mental abilities. An elevated abnormal level of the β -amyloid peptide ($A\beta$) in the brain is the key step in the pathogenesis of AD [1–3]. $A\beta$ is associated with the formation of neurofibrillary tangles [4, 5] with impaired synaptic functions and the loss of neurons. Therefore, a major emphasis of AD therapy has currently been on the removal of $A\beta$ from the affected brains.

Both active and passive immunization approaches were effective in reducing the brain $A\beta$ levels in human patients and in AD mouse models expressing AD-causing mutations of amyloid precursor protein (APP) resulting in a massive production of $A\beta$ and age-dependent amyloid plaque deposition [6–10]. In addition, anti- $A\beta$ immuniza-

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2004 S. Karger AG, Basel
1660–2854/04/0015–0160\$21.00/0

Accessible online at:
www.karger.com/ndd

M. Hasan Mohajeri
Division of Psychiatry Research, University of Zürich
August Forel Strasse 1
CH–8008 Zürich (Switzerland)
Tel. +41 44 634 8872, Fax +41 44 634 8874, E-Mail mohajeri@bli.unizh.ch

Fig. 1. Schematic presentation of different A β fragments that were used to generate the monoclonal antibodies. Letters represent amino acids according to the single letter code. Numbers represent amino acid position within the peptide starting at the N-terminus of the A β peptide. Bars correspond to the peptide that was used for immunization to generate the respective antibody. Balls define the ends of peptides used for immunization. Arrowheads indicate that the used peptides reached to the N-terminus of A β .

tions exerted beneficial effects on cognitive performances of transgenic mouse models of AD [11, 12] and in human subjects [13], providing the functional evidence for the validity of the A β immune therapy. Furthermore, we have recently shown that anti-A β immune therapy protected the neurons against apoptotic stimuli in an AD mouse model [10].

Mechanisms implicated in the reduction of brain A β by antibodies may include acting as a peripheral sink to reduce cerebral A β levels without entering the brain [7]. Alternatively, antibodies may penetrate into the brain, bind the A β and interfere with its aggregation [8, 14, 15]. Finally, upon opsonization of A β by antibodies, the A β /antibody complex is phagocytosed by brain microglial cells in both an Fc receptor-dependent and independent manner [8, 14, 16].

Even though potent in reducing brain A β , immune therapy was shown to provoke aberrant autoimmune response such as meningoencephalitis or cerebral hemorrhages in human subjects or mice [17–19], indicating that under certain circumstances, immunization could lead to adverse side effects. Despite intense research and clinical interest in A β immunization, the mechanisms by which antibodies result in clearing A β from the brain are controversial. It is unclear why some antibodies enter the brain and clear A β , whereas some similar antibodies are ineffective in the same system [8] and what the mechanisms of action of the proposed peripheral sink are. Moreover, the immunization protocol and the epitope of A β chosen for

immunization may affect the outcome of the active immunization [20–22]. Therefore, it is desirable to design a rapid method for predicting the bioactivity of anti-A β antibodies by an in vitro test system. In this study the efficacy of microglia cells to take up and degrade A β in vitro was used for an initial screening of anti-A β antibodies active in vivo. We then verified the bioactivity of anti-A β antibodies with a passive immunization protocol in vivo. We assessed the efficacy of these antibodies to reduce brain A β_{42} levels and showed that the bioactivity of antibodies against A β is dependent on the epitope recognized by these antibodies.

Material and Methods

Hybridoma Cultures and Antibody Production

The monoclonal antibodies were raised against full-length A β peptide or its fragments (fig. 1) and the produced antibodies were tested to recognize the respective peptides and the full-length A β peptide by Western blotting. Hybridoma clones producing antibodies against various fragments of the A β peptide were cultured in OPTI-MEM 1 (Gibco) containing 10% heat-inactivated fetal bovine serum (FBS) and penicillin/streptomycin. The FBS concentration was gradually reduced to a final concentration of 0.1%. Conditioned media were collected and the antibodies were purified via protein A columns (Mo Bi Tech). In brief, the protein A column was washed with 15 ml of 1 $\times$ binding buffer (1 M glycine, 0.15 M NaCl, pH = 8.6) at a flow rate of 1 ml/min. Conditioned media were mixed 1:1 with 2 $\times$ binding buffer and pumped through the column at 1 ml/min at room temperature. Columns were then washed with 30 ml of 1 $\times$ binding buffer and antibodies were eluted with elution buffer (0.1 M citrate,

pH 5.5 and pH 3), desalted and neutralized by dialysis against PBS overnight. The subclass of purified anti-A β antibodies was determined using the monoclonal antibody isotyping kit (Boehringer Mannheim) according to the supplier's protocol.

Primary Microglia Cultures

Primary cultures of mixed glia were prepared from newborn C57BL/6J mice. Meninges, olfactory bulb and hippocampus were removed from brain hemispheres. Neocortical tissue was dissociated by incubation with dissociation solution (0.02% EDTA, 0.24% HEPES, 6.6% trypsin and 0.8% DNase I in DMEM) for 15 min at 37°C followed by an incubation in DMEM (Gibco) containing 10% FBS and 1.6% DNase I for 15 min at 37°C and subsequent triturating by a set of fire-polished glass pipettes of descending diameter. Tissue homogenates were passed through a nylon mesh of 24 μ m pore size (Millipore). 5×10^6 cells were plated per T25 flasks and grown in DMEM medium containing 10% FBS to confluency within 10 days. Culture medium was changed after 24 h and every 3 days thereafter. After 14 days microglial cells started to proliferate and floated at the surface of the medium. Loosely attached cells could be mobilized by gentle shaking of the culture. Microglial cells were harvested by aspiration of the supernatant fluid, centrifuged at 100 *g* for 5 min and resuspended in culture medium. For immunocytochemistry, cells were plated on glass coverslips coated with poly-D-lysine (30–70 kD, Sigma) at a density of 10,000 cells/cm² (low-density cultures). For quantification of A β uptake, cells were cultured in 96-well plates at a density of 100,000 cells/well (high-density cultures). Ten minutes after plating, the microglial cells were adherent and nonadherent cells were eliminated by gently rinsing the cultures with medium. Lectin immunostaining identified more than 95% of cells in these cultures as microglial cells.

In vitro Studies

Synthetic human A β_{42} (1 mg/ml, Bachem) was fibrillized in PBS as described [23]. For qualitative evaluation of A β_{42} uptake in microglial cells by immunohistochemistry, the A β_{42} stock was diluted 1:10 with anti-A β antibody solutions (300 μ g/ml) and incubated overnight at 4°C in a rotary shaker at 5 rpm to generate an A β_{42} /antibody complex. For quantitative determination of microglial uptake by ELISA, A β_{42} stock solution was mixed in a 1:1 ratio with the antibody solutions to generate the A β_{42} /antibody complex.

A β_{42} /antibody complexes were diluted 20 or 33 times in culture medium before incubation with low- or high-density cultures, respectively. Three days later the low-density cultures were washed with PBS, fixed with ice-cold methanol for 10 min and subjected to immunocytochemistry. High-density cultures were incubated with A β_{42} complexes for 2, 24 or 72 h. After several washes, the cultures were then subjected to formic acid extraction and ELISA measurement of cellular A β . Control cultures were incubated with fibrillar A β_{42} alone. To control for unspecific binding of complexes to the culture dish, complexes were also incubated in cell-free wells.

A β Extraction from Microglia Cultures

High-density cultures were incubated with A β_{42} /antibody complex or fibrillar A β_{42} alone for 2, 24 and 72 h. Cells were washed 3 times with PBS, lysed with 70% formic acid and the resulting extracts were neutralized by addition of 20-fold volume of 1 *M* Trizma base. Internalized microglial A β content was quantified by ELISA as described [10, 23]. At least three wells were treated with each antibody in each experiment.

Immunostaining and Western Blotting

After fixation, cultures were washed 3 times with PBS for 5 min and blocked in 10% goat serum for 30 min before incubation with *Griffonia simplicifolia* isolectin B4 (2 μ g/ml, Vector) in PBS containing 0.1% Triton X-100 for 48 h at 4°C. After 3 washes with PBS, cells were incubated with anti-lectin (Vector) and anti-A β antibodies (4G8, Signet) in PBS containing 1% goat serum and 0.1% Triton X-100 for 2 h at room temperature. For double staining against A β and lysosomes, the 4G8 antibody was combined with the anti-lysosomal-associated membrane protein-1 (LAMP-1) antibody (SouthernBiotech). In addition, Iba1 [24, 25] antibody was also used to assess microglia activation.

For analysis of APP processing and microglia activation by Western blotting, mice were anesthetized and perfused transcardially with ice-cold PBS. Frontal parts of the brains reaching from the stereotaxic coordinates interaural 6–5 were homogenized and subjected to Western blotting as described [10, 23]. The remaining parts of the brains were fixed in 4% paraformaldehyde, washed several times in PBS and 35- μ m frontal sections were prepared. After electrophoresis, blots were probed with 6E10 (Signet) and C-terminal APP (Sigma) antibodies to study possible alterations of APP processing due to antibody treatments, as well as Iba1 antibody for quantification of the activation status of microglia. Blots were stripped and probed for β -actin (Abcam) as a loading control [10]. Similarly, to test whether the monoclonal anti-A β antibodies recognize transgenically expressed A β , similar amounts of a brain homogenate of an age-matched SwAPP mouse were loaded onto the gel and probed with the monoclonal anti-A β antibodies (50 μ g/ml).

Passive Immunization

Transgenic mice with neuronal expression of the Swedish double mutation of APP (SwAPP mice) were bred and housed as described [10, 23]. SwAPP mice were passively immunized by intravenous (i.v.) injections of several monoclonal anti-A β antibodies. Each mouse was given four injections into the tail vein of 9 mg antibody/kg body weight at intervals of 5 days beginning at 6–7 weeks of age (*n* = 3–4 per group) [10]. Mice were sacrificed the day after the last antibody injection. Titers of anti-A β antibodies and levels of A β_{42} were measured in sera and compared to the corresponding values prior to the injections as previously described [10, 23], and correlated to A β_{42} levels in the brains of the same mice. The control group comprised untreated age-matched SwAPP littermates (*n* = 4).

Statistical Analysis

Data were collected by investigators blinded to the experimental setup and were analyzed by the nonparametric Mann-Whitney U test. In all graphs, means $\pm$ SEM are shown.

Results

Microglial Cells Internalized Fibrillar A β_{42} and A β_{42} /Antibody Microaggregates in vitro

To discriminate between antibody-dependent and antibody-independent uptake of A β_{42} by microglial cells in vitro, primary microglial cells were incubated for up to 3 days with either fibrillar A β_{42} alone or with A β_{42} /antibody

Fig. 2. Accumulation and phagolysosomal localization of Aβ₄₂ by microglial cells. Aβ₄₂ alone (**a–c**) or Aβ₄₂/antibody complex (**d–i**) were incubated with low-density cultures of primary microglial cells for 24 h and stained with antibodies against Aβ (4G8, **a, d, g**) and lectin (**b, e**) to identify Aβ and the microglial cells, respectively. Microglial cells took up Aβ₄₂ both if it was applied as a complex with specific antibodies (**d–f, g–i**) or if applied alone (**a–c**). 4G8-immunoreactive material was accumulated in granular structures around the nucleus of microglial cells (**a, d** and **c, f** overlay). In addition,

cultures were doubly immunostained against Aβ and a lysosomal marker (LAMP-1). LAMP-1-reactive structures (**h**) and Aβ-positive structures (**g**) showed a broad overlap (**i**), indicating phagolysosomal localization of Aβ in microglial cells. **j** Quantification and kinetics of Aβ₄₂ uptake by microglial cells. Microglial Aβ₄₂ levels extracted by formic acid depended on the antibody used and on the incubation time. Measurements were made at time points 2, 24 and 72 h and represented as absolute cellular Aβ₄₂ content. Scale 100 μm.

complex of Aβ₄₂ with various monoclonal anti-Aβ antibodies generated against the entire Aβ peptide or its N versus C terminal fragments (fig. 1). Immunoreactivity with *G. simplicifolia* isolectin B4 identified the cultured microglia. Cultures were examined by double immunostaining with microglial and Aβ markers. Aβ immunoreactivity was associated with microglial cells, indicating that microglial cells take up fibrillar Aβ₄₂ and the Aβ₄₂/antibody complexes. Microglial cells accumulated Aβ₄₂ both when fibrils were applied alone (fig. 2a–c) and as a complex (fig. 2d–i). To further exclude that Aβ₄₂ is only absorbed to the surface of microglial cells but not internalized, cultures were double-stained for Aβ and a lysosomal antigen (LAMP-1). Aβ and LAMP-1 immunofluorescence showed a broad overlap (fig. 2g–i), indicating that double-

stained structures correspond to phagolysosomes containing Aβ.

To compare the efficacy of the purified antibodies to mediate uptake of fibrillar Aβ₄₂ by microglia, microglia-associated Aβ₄₂ was quantified by ELISA in cell extracts (fig. 2j). These measurements revealed a basal antibody-independent uptake of Aβ₄₂ by microglial cells. Up to 6-fold higher Aβ₄₂ levels were found in microglia cells that were incubated with the Aβ₄₂/antibody complex when compared to incubation of the cells with Aβ alone (fig. 2j). Both efficacy and kinetics of Aβ₄₂ uptake by microglia cells differed between antibodies used for the formation of Aβ₄₂/antibody complexes. Maximum Aβ₄₂ uptake was reached after 3 days for most of the complexes, except for 22C4 where the amount of cellular Aβ₄₂ was highest at

Fig. 3. Passive immunization of SwAPP mice. **a** Elevated levels of anti-Aβ antibody titers were measured at the time of perfusion in sera of all SwAPP mice injected peripherally with identical amounts of purified antibodies. The values are expressed as fold increase, relative to corresponding serum antibody levels of 23 aged-matched untreated SwAPP mice that was set as 100%. **b** Aβ₄₂ concentrations in brain homogenates and sera of SwAPP mice injected peripherally with purified anti-Aβ antibodies. The values are expressed in percent

relative to a 100% baseline of the corresponding values obtained from averaging readings from a control group of 4 noninjected SwAPP littermates (* $p \leq 0.05$, *** $p \leq 0.001$). Note that no group revealed a significant change of the Aβ₄₂ concentrations in serum relative to the baseline. **c** All anti-Aβ antibodies used in the immunization study recognized the human transgenic Aβ expressed in SwAPP brains. The same SwAPP brain homogenate was loaded onto all lanes and the antibody 6E10 served as positive control.

24 h. For 22C4 clone, intracellular Aβ₄₂ levels reached basal levels after 3 days, indicative of a rapid uptake of Aβ₄₂ and its degradation between 1 and 3 days (fig. 2j). While 8G7 mediated a constant increase of microglial Aβ₄₂ over time, 22D4 was completely ineffective in facilitating Aβ₄₂ uptake. Thus, this experimental system allows for quantifying the efficacy of antibodies to mediate Aβ₄₂ uptake in vitro.

To determine whether the varying effects mediated by different antibodies to take up and degrade Aβ₄₂ by microglia cells may be related to different subtypes of IgG, we isotypized the anti-Aβ antibodies used in this study. All antibodies were identified as IgG1-containing κ light chains, thus eliminating the possibility that different antibody subtypes may be responsible for the observed effects.

In vivo Activity of Anti-Aβ Antibodies

The effectiveness of anti-Aβ antibodies to reduce the Aβ levels in vivo was studied by i.v. injection of purified

antibodies into the tail vein of SwAPP mice. Hybridoma clones were selected on the basis of their varying kinetics to mediate Aβ uptake by primary microglia in vitro and attention was paid to choose clones generated against defined fragments of Aβ. In addition, one chosen clone recognized only Aβ₄₀ but not the Aβ₄₂ molecule.

Serum anti-Aβ antibody levels were assessed by analysis of the blood samples taken at the time of perfusion and were compared to baseline antibody levels of 23 untreated age-matched SwAPP littermates (fig. 3a). Antibody titers of the individuals receiving i.v. antibody injections in one group revealed little variation. This finding was expected because a standard amount of purified antibody (adjusted to the body weight of each mouse) was peripherally administered. Strikingly, even though the same amount of antibody was injected for all groups, the level of antibody detectable in serum was lower for 8G7-injected mice (fig. 3a), probably due to a faster turnover of this antibody in vivo.

Finally, A β ₄₂ concentrations in sera and brains of SwAPP mice, peripherally injected with purified antibodies, were assessed (fig. 3b). The injection of the antibody 22C4 caused a 55% reduction of brain A β ₄₂ levels ($p \leq 0.05$), while mice injected with 8G7 and 9G10 antibodies showed an unexpected significant elevation of cerebral A β ₄₂ levels. The elevation of A β ₄₂ levels after 10G8 injections did not reach statistical significance (fig. 3b). The levels of A β ₄₂ correlated significantly in the serum and brains of treated mice (Pearson-Spearman correlation coefficient = 0.646, $p \leq 0.05$). For mice injected with the 22C4 antibody, a strong negative correlation was found between the anti-A β antibody levels in serum and the A β ₄₂ concentrations in the brain (correlation coefficient: -0.98, $p \leq 0.01$). In addition, i.v. antibody injections did not change serum A β ₄₂ levels in any group (fig. 3b). Moreover, Western blot analysis on SwAPP brain homogenates revealed that all antibodies recognized the A β expressed in these brains (fig. 3c).

When compared to untreated brains, no consistent change in APP processing or microglia activation could be detected by Western blotting in brains of mice as a result of passive immunization (not shown).

Discussion

The aim of this study was to set up a system to compare the ability of different monoclonal anti-A β antibodies, raised against different fragments of the A β peptide, to mediate the uptake and degradation of A β ₄₂ in vitro and in vivo. The results of this study show that antibody-mediated A β ₄₂ uptake by primary microglia cells in vitro can be used as a measure to predict the bioactivity of anti-A β antibodies in vivo.

To compare the efficacy at which A β ₄₂ was taken up by the microglial cells when applied as a complex with various antibodies, internalized A β ₄₂ in microglial cells was quantified by ELISA. Different antibodies varied in their activity to mediate uptake of A β , both for the overall amount of A β ₄₂ taken up and also for the kinetics of this uptake, indicating that the degradation of A β ₄₂ is affected by the complexing antibody. These variations cannot be explained by differences in antibody subclasses, which are known to differ in their opsonization capacities because all antibodies included in this test belonged to the same subclass.

Active and passive immunization against fibrillar A β have proven to be powerful tools in reducing or preventing amyloid pathology in transgenic mice overexpressing

human mutant APP [7–9, 11, 12, 15, 21] and in human subjects [6]. It is, however, not yet understood why some anti-A β antibodies are potent in removing A β from the brain, whereas others are ineffective, even though they recognize A β in vitro [8].

Other than by mediating microglial uptake of A β , antibodies against the peptide may also clear A β from the CNS and plasma by inducing a shift in the equilibrium between the two compartments and facilitate A β flux from a central to a peripheral compartment [7, 26]. Moreover, an efficient receptor-mediated bidirectional transport mechanisms for A β was shown at the blood-brain barrier that transports the peptide from the CNS to plasma, as well as from plasma to the CNS [26].

Our data are in agreement with studies showing a scavenger receptor-mediated basal A β uptake by microglial cells without the action of antibodies and that this uptake is increased by anti-A β antibodies [27, 28]. In a similar study, however, an anti-A β antibody increased A β uptake solely 1.5-fold [27], whereas we observed an up to 6-fold increase of A β uptake by microglial cells after antibody treatment. The reasons for the varying capacity of the antibodies to facilitate A β uptake may be found in the epitope recognized by the antibody (17–24 on A β peptide) and in the antibody subtypes (IgG2) used in that study [27]. Furthermore, passive immunization with an antibody against A β of the IgG1 subtype was recently shown to increase the Fc γ receptor expression on microglia in SwAPP mice and led to a reduction of amyloid pathology [29], suggesting an active role of antibodies to promote the clearance of A β by microglial cells in vivo.

We chose young SwAPP mice without plaque pathology to assess antibody-mediated changes in soluble A β , because concentrations of the soluble A β correlate considerably with the degree of cognitive impairment in AD patients [30, 31]. Moreover, we were most interested in A β ₄₂ because it represents the predominant amyloidogenic A β species and its levels are massively increased in the progression of pathology in both AD patients and APP transgenic mouse models.

At the time of perfusion, high levels of anti-A β antibody titers were measured in all mice injected peripherally with purified antibodies. The antibody level in sera of mice injected with 8G7 was markedly lower, even though exactly the same amounts of antibody had been injected. We postulate that these differences are probably attributable to a variability in the biological activity or antibody turnover in vivo. When compared to untreated SwAPP littermates (baseline), brain A β ₄₂ concentrations were significantly lower in mice treated with 22C4 and unex-

pectedly increased in mice injected with antibodies 8G7 and 9G10. We could not assess whether the antibodies were able to effectively bind soluble A β in the brain. All antibodies used here, however, could recognize A β in SwAPP brain homogenates on Western blot level and all have facilitated Fc receptor-mediated microglial uptake of fibrillar A β_{42} in vitro, suggesting that they could interact with the A β peptide.

The absence of an effect on the brain levels of soluble A β_{42} can be explained by the failure of the antibodies to bind A β effectively in the periphery and thus exert the effect of a peripheral sink or by the inability to enter the brain and induce enhanced microglial uptake of A β . The observed increase of A β_{42} concentrations in the brains of mice injected with antibodies 8G7 and 9G10, however, are in stark contrast to most published studies on the peripheral passive immunization with anti-A β antibodies, suggesting that anti-A β antibodies differ in their ability to reduce A β_{42} levels when used in the same experimental setup. Similar increases in brain A β levels after anti-A β immunization, however, have been shown in other studies [32, 33], indicating again that a shift between A β levels of the CNS and periphery is bidirectional and

the net effect depends on the antibody used and on the mode of antibody application.

In the present study we show that the bioactivity of anti-A β antibodies depended on the epitope recognized. More importantly, the ability of an anti-A β antibody to mediate A β_{42} uptake by primary microglial cells can predict its bioactivity to reduce the brain levels of A β_{42} in vivo. The collected data establish a framework for the evaluation and identification of in vivo active antibodies. In this respect, our data will help to design further experiments aiming at the refinement of amyloid-lowering strategies in vivo.

Acknowledgments

We thank Dr. Karen K. Hsiao (University of Minnesota, Minneapolis, Minn.) for providing SwAPP mice, Evotec Neurosciences for providing the anti-A β hybridoma clones and Dr. Yoshinori Imai (National Institute of Science, Tokyo) for providing the Iba1 antibody. This work was funded partially by the Swiss National Science Foundation, the Stambach Foundation, NCCR on Neural Plasticity and Regeneration, and the European Union under the programme 'Quality of Life and Management of Living Resources', Key Action 3 'The Cell Factory', Contract No. QLK3-CT-2001-02362.

References

- Selkoe DJ: Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. *J Alzheimers Dis* 2001;3:75–80.
- Selkoe DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. *Nature* 1999;399(6738 suppl):A23–A31.
- Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. *Science* 2002;297:353–356.
- Lewis J, et al: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. *Science* 2001;293:1487–1491.
- Gotz J, et al: Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils. *Science* 2001;293:1491–1495.
- Nicoll JA, et al: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. *Nat Med* 2003;9:448–452.
- DeMattos RB, et al: Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci USA* 2001;98:8850–8855.
- Bard F, et al: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. *Nat Med* 2000;6:916–919.
- Schenk D, et al: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. *Nature* 1999;400:173–177.
- Mohajeri MH, et al: Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. *J Biol Chem* 2002;277:33012–33017.
- Morgan D, et al: Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. *Nature* 2000;408:982–985.
- Janus C, et al: Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. *Nature* 2000;408:979–982.
- Hock C, et al: Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. *Neuron* 2003;38:547–554.
- Bacskaï BJ, et al: Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. *Nat Med* 2001;7:369–372.
- Frenkel D, Katz O, Solomon B: Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration. *Proc Natl Acad Sci USA* 2000;97:11455–11459.
- Bacskaï BJ, et al: Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. *J Neurosci* 2002;22:7873–7878.
- Pfeiffer M, et al: Cerebral hemorrhage after passive anti-Abeta immunotherapy. *Science* 2002;298:1379.
- Furlan R, et al: Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. *Brain* 2003;126:285–291.
- Schenk D: Amyloid-beta immunotherapy for Alzheimer's disease: The end of the beginning. *Nat Rev Neurosci* 2002;3:824–828.
- Leverone JF, et al: Abeta1–15 is less immunogenic than Abeta1–40/42 for intranasal immunization of wild-type mice but may be effective for 'boosting'. *Vaccine* 2003;21:2206–2215.
- Lemere CA, et al: Intranasal immunotherapy for the treatment of Alzheimer's disease: *Escherichia coli* LT and LT(R192G) as mucosal adjuvants. *Neurobiol Aging* 2002;23:991–1000.

- 22 Lemere CA, et al: Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. *Neurobiol Dis* 2003;14:10–18.
- 23 Mohajeri MH, Wollmer MA, Nitsch RM: Abeta 42-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo. *J Biol Chem* 2002;277:35460–35465.
- 24 Ohsawa K, et al: Involvement of Iba1 in membrane ruffling and phagocytosis of macrophages/microglia. *J Cell Sci* 2000;113:3073–3084.
- 25 Imai Y, et al: A novel gene *iba1* in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. *Biochem Biophys Res Commun* 1996;224:855–862.
- 26 Shibata M, et al: Clearance of Alzheimer's amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. *J Clin Invest* 2000;106:1489–1499.
- 27 Brazil MI, Chung H, Maxfield FR: Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia. *J Biol Chem* 2000;275:16941–16947.
- 28 Paresce DM, Ghosh RN, Maxfield FR: Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. *Neuron* 1996;17:553–565.
- 29 Wilcock DM, et al: Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. *J Neurosci* 2004;24:6144–6151.
- 30 Wang J, et al: The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. *Exp Neurol* 1999;158:328–337.
- 31 Naslund J, et al: Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. *JAMA* 2000;283:1571–1577.
- 32 Koller MF, et al: Immunization of mice with an AβHsp70 vaccine elicits anti-Aβ antibodies and increased cerebral Aβ-levels. *Neurodegener Dis* 2004;1:20–28.
- 33 Vehmas AK, et al: beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APP^{swe}/PS1^{DeltaE9} mice, as detected by SELDI-TOF-based ProteinChip technology. *DNA Cell Biol* 2001;20:713–721.